annual EBITDA:
-$523.98M-$17.66M(-3.49%)Summary
- As of today (June 22, 2025), NTLA annual EBITDA is -$523.98 million, with the most recent change of -$17.66 million (-3.49%) on December 31, 2024.
- During the last 3 years, NTLA annual EBITDA has fallen by -$263.02 million (-100.79%).
- NTLA annual EBITDA is now -3905.64% below its all-time high of -$13.08 million, reached on December 31, 2015.
Performance
NTLA EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
quarterly EBITDA:
-$118.31M+$15.57M(+11.63%)Summary
- As of today (June 22, 2025), NTLA quarterly EBITDA is -$118.31 million, with the most recent change of +$15.57 million (+11.63%) on March 31, 2025.
- Over the past year, NTLA quarterly EBITDA has dropped by -$6.82 million (-6.12%).
- NTLA quarterly EBITDA is now -10081.50% below its all-time high of -$1.16 million, reached on March 31, 2015.
Performance
NTLA quarterly EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
TTM EBITDA:
-$530.80M-$6.82M(-1.30%)Summary
- As of today (June 22, 2025), NTLA TTM EBITDA is -$530.80 million, with the most recent change of -$6.82 million (-1.30%) on March 31, 2025.
- Over the past year, NTLA TTM EBITDA has dropped by -$22.90 million (-4.51%).
- NTLA TTM EBITDA is now -45579.52% below its all-time high of -$1.16 million, reached on March 31, 2015.
Performance
NTLA TTM EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
EBITDA Formula
EBITDA = Net Income + Interest + Taxes + Depreciation + Amortization
NTLA EBITDA Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -3.5% | -6.1% | -4.5% |
| 3 y3 years | -100.8% | +17.0% | -48.0% |
| 5 y5 years | -419.9% | -275.5% | -383.5% |
NTLA EBITDA Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -100.8% | at low | -22.6% | +17.0% | -48.0% | at low |
| 5 y | 5-year | -419.9% | at low | -346.4% | +17.0% | -383.5% | at low |
| alltime | all time | -3905.6% | at low | <-9999.0% | +17.0% | <-9999.0% | at low |
NTLA EBITDA History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Mar 2025 | - | -$118.31M(-11.6%) | -$530.80M(+1.3%) |
| Dec 2024 | -$523.98M(+3.5%) | -$133.88M(-5.8%) | -$523.98M(-0.7%) |
| Sep 2024 | - | -$142.16M(+4.2%) | -$527.52M(+2.6%) |
| Jun 2024 | - | -$136.44M(+22.4%) | -$514.18M(+1.2%) |
| Mar 2024 | - | -$111.49M(-18.9%) | -$507.90M(+0.3%) |
| Dec 2023 | -$506.31M(+12.4%) | -$137.43M(+6.7%) | -$506.31M(+6.2%) |
| Sep 2023 | - | -$128.82M(-1.0%) | -$476.94M(+5.6%) |
| Jun 2023 | - | -$130.16M(+18.4%) | -$451.71M(+8.1%) |
| Mar 2023 | - | -$109.91M(+1.7%) | -$418.01M(-7.2%) |
| Dec 2022 | -$450.59M(+72.7%) | -$108.06M(+4.3%) | -$450.59M(+7.0%) |
| Sep 2022 | - | -$103.58M(+7.4%) | -$421.07M(+8.6%) |
| Jun 2022 | - | -$96.46M(-32.3%) | -$387.70M(+8.1%) |
| Mar 2022 | - | -$142.49M(+81.4%) | -$358.62M(+37.4%) |
| Dec 2021 | -$260.96M(+100.3%) | -$78.53M(+11.9%) | -$260.96M(+16.9%) |
| Sep 2021 | - | -$70.21M(+4.2%) | -$223.22M(+24.3%) |
| Jun 2021 | - | -$67.38M(+50.3%) | -$179.51M(+25.0%) |
| Mar 2021 | - | -$44.83M(+9.9%) | -$143.60M(+10.2%) |
| Dec 2020 | -$130.27M | -$40.80M(+54.0%) | -$130.27M(+10.7%) |
| Sep 2020 | - | -$26.50M(-15.8%) | -$117.68M(+2.2%) |
| Jun 2020 | - | -$31.47M(-0.1%) | -$115.13M(+4.9%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Mar 2020 | - | -$31.51M(+11.7%) | -$109.78M(+8.9%) |
| Dec 2019 | -$100.78M(+16.6%) | -$28.20M(+17.8%) | -$100.78M(+9.4%) |
| Sep 2019 | - | -$23.95M(-8.3%) | -$92.09M(+1.1%) |
| Jun 2019 | - | -$26.12M(+16.1%) | -$91.10M(+4.1%) |
| Mar 2019 | - | -$22.51M(+15.3%) | -$87.50M(+1.3%) |
| Dec 2018 | -$86.41M(+29.8%) | -$19.52M(-14.9%) | -$86.41M(-4.8%) |
| Sep 2018 | - | -$22.95M(+1.9%) | -$90.77M(+9.5%) |
| Jun 2018 | - | -$22.52M(+5.2%) | -$82.91M(+9.5%) |
| Mar 2018 | - | -$21.42M(-10.3%) | -$75.69M(+13.7%) |
| Dec 2017 | -$66.56M(+114.3%) | -$23.88M(+58.3%) | -$66.56M(+25.4%) |
| Sep 2017 | - | -$15.09M(-1.4%) | -$53.10M(+16.8%) |
| Jun 2017 | - | -$15.31M(+24.6%) | -$45.44M(+23.4%) |
| Mar 2017 | - | -$12.29M(+18.0%) | -$36.84M(+18.6%) |
| Dec 2016 | -$31.05M(+137.4%) | -$10.42M(+40.2%) | -$31.05M(+19.5%) |
| Sep 2016 | - | -$7.43M(+10.9%) | -$26.00M(+19.4%) |
| Jun 2016 | - | -$6.70M(+3.0%) | -$21.77M(+18.1%) |
| Mar 2016 | - | -$6.51M(+21.4%) | -$18.43M(+40.9%) |
| Dec 2015 | -$13.08M | -$5.36M(+67.2%) | -$13.08M(+69.4%) |
| Sep 2015 | - | -$3.21M(-4.5%) | -$7.72M(+71.0%) |
| Jun 2015 | - | -$3.35M(+188.7%) | -$4.52M(+288.7%) |
| Mar 2015 | - | -$1.16M | -$1.16M |
FAQ
- What is Intellia Therapeutics annual EBITDA?
- What is the all time high annual EBITDA for Intellia Therapeutics?
- What is Intellia Therapeutics annual EBITDA year-on-year change?
- What is Intellia Therapeutics quarterly EBITDA?
- What is the all time high quarterly EBITDA for Intellia Therapeutics?
- What is Intellia Therapeutics quarterly EBITDA year-on-year change?
- What is Intellia Therapeutics TTM EBITDA?
- What is the all time high TTM EBITDA for Intellia Therapeutics?
- What is Intellia Therapeutics TTM EBITDA year-on-year change?
What is Intellia Therapeutics annual EBITDA?
The current annual EBITDA of NTLA is -$523.98M
What is the all time high annual EBITDA for Intellia Therapeutics?
Intellia Therapeutics all-time high annual EBITDA is -$13.08M
What is Intellia Therapeutics annual EBITDA year-on-year change?
Over the past year, NTLA annual EBITDA has changed by -$17.66M (-3.49%)
What is Intellia Therapeutics quarterly EBITDA?
The current quarterly EBITDA of NTLA is -$118.31M
What is the all time high quarterly EBITDA for Intellia Therapeutics?
Intellia Therapeutics all-time high quarterly EBITDA is -$1.16M
What is Intellia Therapeutics quarterly EBITDA year-on-year change?
Over the past year, NTLA quarterly EBITDA has changed by -$6.82M (-6.12%)
What is Intellia Therapeutics TTM EBITDA?
The current TTM EBITDA of NTLA is -$530.80M
What is the all time high TTM EBITDA for Intellia Therapeutics?
Intellia Therapeutics all-time high TTM EBITDA is -$1.16M
What is Intellia Therapeutics TTM EBITDA year-on-year change?
Over the past year, NTLA TTM EBITDA has changed by -$22.90M (-4.51%)